Crestovo

Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota that harnesses the human gut microbiome.

Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota (FSM) that harnesses the human gut microbiome. Crestovo is advancing the foundational clinical research of the company’s academic collaborators, Dr. Thomas Borody, Dr. Alexander Khoruts and Dr. Michael Sadowsky, which demonstrated in-human validation of an orally-available, microbiota-based product across a variety of serious diseases and unmet medical needs, including recurrent CDI. Crestovo’s lead Full-Spectrum Microbiota (FSM) product, CP101, is currently being evaluated in the PRISM 3 clinical trial in patients with recurrent CDI.